Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Note: Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.

Cancer research·2026
Same author

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.

JCO precision oncology·2026
Same author

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.

The New England journal of medicine·2026
Same author

Skin health in oncology: evidence-based skin care for cancer patients.

The oncologist·2026
Same author

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime Time?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Mar 24, 2026

Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata
07:58

Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata

Published on: November 23, 2017

8.3K

Managing Liposarcomas: Cutting Through the Fat.

Gulam A Manji1, Gary K Schwartz2

  • 1Columbia University School of Medicine, New York, NY Gam2140@cumc.columbia.edu.

Journal of Oncology Practice
|March 11, 2016
PubMed
Summary

Liposarcomas require subtype classification for effective treatment. Differentiating subtypes guides surgical or chemotherapeutic strategies, including targeted therapies for better patient outcomes.

More Related Videos

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

3.0K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

Related Experiment Videos

Last Updated: Mar 24, 2026

Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata
07:58

Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata

Published on: November 23, 2017

8.3K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

3.0K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

Area of Science:

  • Oncology
  • Genetics
  • Surgical Pathology

Background:

  • Liposarcomas are common soft tissue sarcomas with over 50 subtypes.
  • They are categorized into four main histologic subtypes: atypical lipomatous tumor/well-differentiated, dedifferentiated, myxoid (round cell), and pleomorphic liposarcoma.

Purpose of the Study:

  • To highlight the heterogeneity of liposarcomas.
  • To emphasize the importance of subtype classification for treatment planning.
  • To review current and emerging therapeutic strategies based on liposarcoma subtypes.

Main Methods:

  • Review of current literature on liposarcoma classification and treatment.
  • Discussion of diagnostic tools including histologic and molecular analysis.
  • Analysis of therapeutic responses to chemotherapy and targeted agents.

Main Results:

  • Surgical resection is definitive for resectable disease, with surveillance for certain well-differentiated liposarcomas.
  • Chemotherapy (anthracycline, ifosfamide, gemcitabine, docetaxel) is first-line for inoperable myxoid or pleomorphic liposarcomas.
  • Trabectedin and eribulin show efficacy in later lines of therapy for specific subtypes.

Conclusions:

  • Liposarcoma treatment must be subtype-specific.
  • Histologic and molecular subclassification are critical before treatment.
  • Targeted therapies, such as those targeting CDK4 and MDM2, are emerging as promising options.